Annual Report and Accounts

RNS Number : 8979A

ReNeuron Group plc

07 August 2008

 



2007/08 Annual Report and Accounts

Guildford, UK, 7 August 2008: ReNeuron Group plc (LSE: RENE.L) gives notice that its Annual Report and Accounts for the year ended 31 March 2008 have been sent to shareholders, and are also now available on the Company's website at www.reneuron.com.  

Copies have also been submitted to the UK Listing Authority for publication through the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

Enquiries:

ReNeuron 

Michael Hunt, Chief Executive Officer

Tel: [phone]

Financial Dynamics

Claire Rowell

Tel: [phone]

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies targeting significant unmet or poorly-met clinical needs.  

ReNeuron has used its proprietary, patented cell expansion technology to generate genetically stable stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation. ReNeuron's clinically-tested cell encapsulation technology provides a method of protecting cells when transplanted, as well as reducing or eliminating the host immune response that might otherwise occur post-transplantation.

ReNeuron is filing for approval to commence initial clinical studies with its lead ReN001 stem cell therapy for disabled stroke patients. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US. In addition to its stroke programme, ReNeuron is developing stem cell therapies for a number of neurodegenerative diseases and other conditions, including Parkinson's disease, Type 1 diabetes and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. ReNeuron's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by US-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

Data sources: UK Stroke Association; American Stroke Association

 

END

 

 

ACSILFVSTIIDIIT